Daniela Linzner

Toggle Menu

Daniela Linzner

Senior Research Scientist, Immunology Services

Daniela Linzner, Ph.D., focuses on assay development, immunotoxicity, potency and immunogenicity studies of immune-modulating products, cell-based therapies and biologic therapeutics. She has particular expertise in the development and validation of Good Laboratory Practices (GLP)- and Current Good Manufacturing Practices (cGMP)-compliant enzyme-linked immunosorbent assays (ELISAs) for detection and characterization of biologic agents.

Linzner developed and validated ELISA methods for determining drug levels of several biologic products and is a lead contributor in toxicity studies. One of her areas of specialty has been development and validation of immunoassays, including cell-based immune functional assays, ELISAs, enzyme-linked immunospots (ELISPOTs) and multiplexed assays on the meso scale discovery (MSD) and Luminex platforms. She has extensive knowledge of multi-color fluorescence-activated cell sorting (FACS)-based methods, protein biochemistry and molecular biology.

Prior to joining SRI, Linzner was a senior healthcare scientist at Great Ormond Street Hospital for Children and the University College London, Institute of Child Health in London, where she developed assays for the clinical diagnostic of rare genetic disorders (autoimmune lymphoproliferative syndrome, ALPS; familial hemophagocytic lymphohistiocytosis, FLH; and severe combined immunodeficiency, SCID).

Linzner received her degrees in Germany, including a B.S. in biology from the University of Ulm, M.S. in biology from University of Stuttgart-Hohenheim and Ph.D. in immunology from Eberhardt-Karls-University of Tübingen.

Daniela Linzner